Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011

New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384

Defining the clinical course of multiple sclerosis

LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762

Generalized Linear Models

Schuenemeyer, J. H., McCullagh, P. J., & Nelder, J. A. (1992) · Technometrics · doi:10.2307/1269238 · Cited by 2,702

Interferon beta‐lb in the treatment of multiple sclerosis

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) · Neurology · doi:10.1212/wnl.45.7.1277 · Cited by 971

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

Miller, D. (1998) · Brain · doi:10.1093/brain/121.1.3 · Cited by 553

Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology

Brück, W., Bitsch, A., Kolenda, H., Brück, Y., Stiefel, M., & Lassmann, H. (1997) · Annals of Neurology · doi:10.1002/ana.410420515 · Cited by 520

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up

O’Riordan, J. I. (1998) · Brain · doi:10.1093/brain/121.3.495 · Cited by 480

Accumulation of hypointense lesions ("black holes") on T 1 spin-echo MRI correlates with disease progression in multiple sclerosis

Truyen, L., van Waesberghe, J. H. T. M., van Walderveen, M. A. A., van Oosten, B. W., Polman, C. H., Hommes, O. R., Adèr, H. J., & Barkhof, F. (1996) · Neurology · doi:10.1212/wnl.47.6.1469 · Cited by 461

Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

Katz, D., Taubenberger, J. K., Cannella, B., McFarlin, D. E., Raine, C. S., & McFarland, H. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340507 · Cited by 387

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials

Boneschi, F. M., Rovaris, M., Johnson, K. P., Miller, A., Wolinsky, J. S., Ladkani, D., Shifroni, G., Comı, G., & Filippi, M. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms932oa · Cited by 81

Neuroimaging In Multiple Sclerosis

Zivadinov, R., & Cox, J. L. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)79020-7 · Cited by 81

Blood brain barrier (BBB)-disruption in intracortical silicon microelectrode implants

Bennett, C., Samikkannu, M., Mohammed, F. S., Dietrich, W. D., Rajguru, S. M., & Prasad, A. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.036 · Cited by 81

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

Ostkamp, P., Salmen, A., Pignolet, B., Görlich, D., Andlauer, T. F. M., Schulte‐Mecklenbeck, A., González‐Escamilla, G., Bucciarelli, F., Gennero, I., Breuer, J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2018457118 · Cited by 83

Role of MRI in multiple sclerosis II: brain and spinal cord atrophy.

Zivadinov, R., & Bakshi, R. (2004) · Frontiers in Bioscience · doi:10.2741/1262 · Cited by 80

Mitochondria in neuroinflammation – Multiple sclerosis (MS), leber hereditary optic neuropathy (LHON) and LHON-MS

Bargiela, D., & Chinnery, P. F. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.06.051 · Cited by 79

Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage

Weiner, H. L., Guttmann, C. R. G., Khoury, S. J., Orav, E. J., Hohol, M. J., Kikinis, R., & Jolesz, F. A. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00273-8 · Cited by 78

Clinical correlations of brain lesion distribution in multiple sclerosis

Vellinga, M. M., Geurts, J. J. G., Rostrup, E., Uitdehaag, B. M. J., Polman, C. H., Barkhof, F., & Vrenken, H. (2009) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21679 · Cited by 77

Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis

Lukas, C., Minneboo, A., de Groot, V., Moraal, B., Knol, D. L., Polman, C. H., Barkhof, F., & Vrenken, H. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.199968 · Cited by 77

A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS

Martinelli, V., Rocca, M. A., Annovazzi, P. O. L., Pulizzi, A., Rodegher, M. E., Boneschi, F. M., Scotti, R., Falini, A., Sormani, M. P., Comı, G., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c3fd5b · Cited by 75

The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome

Zivadinov, R., Stosic, M., Cox, J. L., Ramasamy, D. P., & Dwyer, M. G. (2008) · Journal of Neurology · doi:10.1007/s00415-008-1009-1 · Cited by 74

Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis

Furby, J., Hayton, T., Anderson, V., Altmann, D., Brenner, R., Chataway, J., Hughes, R. A. C., Smith, K., Miller, D. H., & Kapoor, R. (2008) · Multiple Sclerosis · doi:10.1177/1352458508093617 · Cited by 80

A modified protocol to improve the detection of enhancing brain and spinal cord leasions in multiple sclerosis

Silver, N., Good, C. D., Sormani, M. P., MacManus, D. G., Thompson, A. J., Filippi, M., & Miller, D. (2001) · Journal of Neurology · doi:10.1007/s004150170229 · Cited by 74

Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis

Oh, J., Arnold, D. L., Cree, B., Ionete, C., Kim, H.-J., Sormani, M. P., Syed, S., Chen, Y., Maxwell, C. R., Benoit, P., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415985 · Cited by 80

Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials

Lavery, A. M., Verhey, L. H., & Waldman, A. T. (2014) · Multiple Sclerosis International · doi:10.1155/2014/262350 · Cited by 73

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

Arnold, D. L., Gold, R., Kappos, L., Bar‐Or, A., Giovannoni, G., Selmaj, K. W., Yang, M., Zhang, R., Stephan, M., Sheikh, S. I., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7412-x · Cited by 73

Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study

Silver, N., Tofts, P., Symms, M., Barker, G. J., Thompson, A., & Miller, D. (2001) · Multiple Sclerosis · doi:10.1177/135245850100700201 · Cited by 76

Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations

Bergh, F. T., Kümpfel, T., Schumann, E. M., Held, U., Schwan, M., Blazevic, M., Wismüller, A., Holsboer, F., Yassouridis, A., Uhr, M., et al. (2006) · BMC Neurology · doi:10.1186/1471-2377-6-19 · Cited by 73

Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions

Mehling, M., Kappos, L., & Derfuss, T. J. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0216-9 · Cited by 74

Microglia Regulate Blood–Brain Barrier Integrity via MiR‐126a‐5p/MMP9 Axis during Inflammatory Demyelination

Yu, Z., Xue, F., Liu, W., Sun, R. X., Zhou, J., Pu, Y., Zhao, M., Sun, D., Xiang, Z., Liu, P., et al. (2022) · Advanced Science · doi:10.1002/advs.202105442 · Cited by 71

Longitudinal MR Imaging of Iron in Multiple Sclerosis: An Imaging Marker of Disease

Walsh, A. J. L., Blevins, G., Lebel, R. M., Seres, P., Emery, D. J., & Wilman, A. H. (2013) · Radiology · doi:10.1148/radiol.13130474 · Cited by 70

EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis

Filippi, M., Rocca, M. A., Arnold, D. L., Bakshi, R., Barkhof, F., Stefano, N. D., Fazekas, F., Frohman, E. M., & Wolinsky, J. S. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01543.x · Cited by 68

Gene and protein expression profiling of human cerebral endothelial cells activated with tumor necrosis factor-$alpha;

Franzén, B. (2003) · Molecular Brain Research · doi:10.1016/s0169-328x(03)00185-2 · Cited by 70

Current approved options for treating patients with multiple sclerosis

Rizvi, S., & Agius, M. A. (2004) · Neurology · doi:10.1212/wnl.63.12_suppl_6.s8 · Cited by 70

Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis

Tortorella, C., Bellacosa, A., Paolicelli, D., Fuiani, A., Monte, E. D., Simone, I. L., Giaquinto, P., Livrea, P., & Trojano, M. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.08.006 · Cited by 70

Is physical exercise a multiple sclerosis disease modifying treatment?

Motl, R. W., & Pilutti, L. A. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1193008 · Cited by 70

Early clinical markers of aggressive multiple sclerosis

Malpas, C. B., Manouchehrinia, A., Sharmin, S., Roos, I., Horáková, D., Havrdová, E., Trojano, M., Izquierdo, G., Eichau, S., Bergamaschi, R., et al. (2020) · Brain · doi:10.1093/brain/awaa081 · Cited by 68

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

Miller, D. H., Fox, R. J., Phillips, J. T., Hutchinson, M., Havrdová, E., Kita, M., Wheeler‐Kingshott, C. A. M. G., Tozer, D. J., MacManus, D. G., Yousry, T. A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001360 · Cited by 65

Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis

Horsfield, M. A., Barker, G. J., Barkhof, F., Miller, D. H., Thompson, A. J., & Filippi, M. (2003) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.10266 · Cited by 65

Temporal relationship between environmental influenza A and Epstein–Barr viral infections and high multiple sclerosis relapse occurrence

Oikonen, M., Laaksonen, M., Aalto, V., Ilonen, J., Salonen, R., Erälinna, J.-P., Panelius, M., & Salmi, A. A. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458510394397 · Cited by 64

Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis

Young, K. L., Brandt, A. U., Petzold, A., Reitz, L. Y., Lintze, F., Paul, F., Martinꝉ, R., & Schippling, S. (2013) · European Journal of Neurology · doi:10.1111/ene.12070 · Cited by 63

Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis

Lattanzi, S., Cagnetti, C., Danni, M. C., Provinciali, L., & Silvestrini, M. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8505-0 · Cited by 63

Body Temperature Is Elevated and Linked to Fatigue in Relapsing-Remitting Multiple Sclerosis, Even Without Heat Exposure

Sumowski, J. F., & Leavitt, V. M. (2014) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2014.02.004 · Cited by 61

Hypothalamo–pituitary–adrenal axis activity predicts disease progression in multiple sclerosis

Gold, S. M., Raji, A., Huitinga, I., Wiedemann, K., Schulz, K., & Heesen, C. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.04.014 · Cited by 60

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

Radue, E. W., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Rudick, R. A., LUBLIN, F. D., Weinstock‐Guttman, B., Wynn, D. R., Fisher, E., et al. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.02.012 · Cited by 60

Role of MRI in diagnosis and treatment of multiple sclerosis

Sahraian, M. A., & Eshaghi, A. (2010) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2010.03.022 · Cited by 61

Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets

Sormani, M. P. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.4.494 · Cited by 59

Cerebral Atrophy Measurement in Clinically Isolated Syndromes and Relapsing Remitting Multiple Sclerosis: A Comparison of Registration‐Based Methods

Anderson, V., Fernando, K., Davies, G., Rashid, W., Frost, C., Fox, N. C., & Miller, D. H. (2007) · Journal of Neuroimaging · doi:10.1111/j.1552-6569.2006.00081.x · Cited by 59

MRI activity and neutralising antibody as predictors of response to interferon treatment in multiple sclerosis

Durelli, L., Barbero, P., Bergui, M., Versino, E., Bassano, M. A., Verdun, E., Rivoiro, C., Ferrero, C., Picco, E., Ripellino, P., et al. (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.130229 · Cited by 60

Clinical–MRI correlations in a European trial of interferon beta-1b in secondary progressive MS

Molyneux, P. D., Barker, G. J., Barkhof, F., Beckmann, K., Dahlke, F., Filippi, M., Ghazi, M. K. K., Hahn, D. W., MacManus, D. G., Polman, C. H., et al. (2001) · Neurology · doi:10.1212/wnl.57.12.2191 · Cited by 59

Evoked potentials for evaluation of multiple sclerosis

Fuhr, P., & Kappos, L. (2001) · Clinical Neurophysiology · doi:10.1016/s1388-2457(01)00687-3 · Cited by 59

Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis

Pittock, S. J., Weinshenker, B. G., Noseworthy, J. H., Lucchinetti, C. F., Keegan, M., Wingerchuk, D. M., Carter, J., Shuster, E. A., & Rodriguez, M. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.611 · Cited by 58

Identifying and treating patients with suboptimal responses

Cohen, B. A., Khan, O., Jeffery, D., Bashir, K., Rizvi, S., Fox, E., Agius, M. A., Bashir, R., Collins, T. E., Herndon, R. M., et al. (2004) · Neurology · doi:10.1212/wnl.63.12_suppl_6.s33 · Cited by 57

Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes

Soon, D. T. L., Tozer, D. J., Altmann, D. R., Tofts, P. S., & Miller, D. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458507076970 · Cited by 57

Short-term prognosis in early relapsing-remitting multiple sclerosis

Scott, T. F. M., Schramke, C. J., Novero, J., & Chieffe, C. (2000) · Neurology · doi:10.1212/wnl.55.5.689 · Cited by 56

Nanomedicine in autoimmunity

Clemente‐Casares, X., & Santamaría, P. (2014) · Immunology Letters · doi:10.1016/j.imlet.2013.12.018 · Cited by 56

The Role of MRI in the Diagnosis of MS

Pretorius, P. M., & Quaghebeur, G. (2003) · Clinical Radiology · doi:10.1016/s0009-9260(03)00089-8 · Cited by 55

Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials

Barkhof, F., Held, U., Simon, J. H., Däumer, M., Fazekas, F., Filippi, M., Frank, J. A., Kappos, L., Li, D. K. B., Menzler, S., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000183149.87975.32 · Cited by 54

Prospects of modeling poststroke epileptogenesis

Reddy, D. S., Bhimani, A. A., Kuruba, R., Park, M. J., & Sohrabji, F. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23836 · Cited by 54

Sex-Based Differences in Multiple Sclerosis (MS): Part II: Rising Incidence of Multiple Sclerosis in Women and the Vulnerability of Men to Progression of this Disease

Dunn, S. E., Gunde, E., & Lee, H. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_370 · Cited by 57

Multivariate pattern classification of gray matter pathology in multiple sclerosis

Bendfeldt, K., Klöppel, S., Nichols, T. E., Smieskova, R., Küster, P., Traud, S., Mueller‐Lenke, N., Naegelin, Y., Kappos, L., Radue, E. W., et al. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.12.070 · Cited by 52

Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives

Bar-Zohar, D., Agosta, F., Goldstaub, D., & Filippi, M. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458507088102 · Cited by 50

Multiple sclerosis and cerebral endothelial dysfunction: Mechanisms

Alexander, J. S., Zivadinov, R., Maghzi, A., Ganta, V. C., Harris, M. K., & Minagar, A. (2010) · Pathophysiology · doi:10.1016/j.pathophys.2010.04.002 · Cited by 51

Deep learning segmentation of gadolinium-enhancing lesions in multiple sclerosis

Coronado, I., Gabr, R. E., & Narayana, P. A. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520921364 · Cited by 49

Frequency of subclinical lacunar infarcts in ischemic leukoaraiosis and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.

O'Sullivan, M. J., Rich, P. M., Barrick, T. R., Clark, C. A., & Markus, H. S. (2003) · PubMed Central · Cited by 50

Magnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study

Barkhof, F., Polman, C. H., Radue, E. W., Kappos, L., Freedman, M. S., Edan, G., Hartung, H., Miller, D. H., Montalbán, X., Poppe, P. A., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.9.1292 · Cited by 48

Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years

Schlaeger, R., Schindler, C., Grize, L., Dellas, S., Radue, E. W., Kappos, L., & Fuhr, P. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514525867 · Cited by 48

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis

O'Connor, P. W., Miller, D. H., Riester, K. A., Yang, M., Panzara, M. A., Dalton, C. M., Miszkiel, K., Khan, O., Rice, G. P., Sheremata, W. A., et al. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1205oa · Cited by 48

Systematic review of prediction models in relapsing remitting multiple sclerosis

Brown, F. S., Glasmacher, S. A., Kearns, P. K. A., MacDougall, N., Hunt, D. P. J., Connick, P., & Chandran, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233575 · Cited by 49

Perspectives for Managed Care Organizations on the Burden of Multiple Sclerosis and the Cost-Benefits of Disease-Modifying Therapies

Owens, G. M., Olvey, E. L., Skrepnek, G. H., & Pill, M. W. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.s1.s41 · Cited by 48

Sex-Based Differences in Multiple Sclerosis (Part I): Biology of Disease Incidence

Dunn, S. E., Lee, H., Pavri, F. R., & Zhang, M. A. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_371 · Cited by 47

Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses

Petkau, J., Reingold, S. C., Held, U., Cutter, G., Fleming, T., Hughes, M., Miller, D., McFarland, H., & Wolinsky, J. S. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458507088104 · Cited by 47

The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis

Bakshi, R., Hutton, G. J., Miller, J. R., & Radue, E. (2004) · Neurology · doi:10.1212/wnl.63.11_suppl_5.s3 · Cited by 44

The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS

Saindane, A. M., Ge, Y., Udupa, J. K., Babb, J. S., Mannon, L. J., & Grossman, R. I. (2000) · Neurology · doi:10.1212/wnl.55.1.61 · Cited by 47

Increase in the iron content of the substantia nigra and red nucleus in multiple sclerosis and clinically isolated syndrome: A 7 Tesla MRI study

Blazejewska, A. I., Al‐Radaideh, A., Wharton, S., Lim, S., Bowtell, R. W., Constantinescu, C. S., & Gowland, P. A. (2014) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24644 · Cited by 46

Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis

Young, P. J., Lederer, C., Eder, K., Däumer, M., Neiß, A., Polman, C. H., & Kappos, L. (2006) · Neurology · doi:10.1212/01.wnl.0000234064.17156.03 · Cited by 46

Within‐lesion differences in quantitative MRI parameters predict contrast enhancement in multiple sclerosis

Jurcoane, A., Wagner, M., Schmidt, C. G., Mayer, C., Gracien, R., Hirschmann, M. M., Deichmann, R., Volz, S., Ziemann, U., & Hattingen, E. (2013) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24107 · Cited by 45

Spatial diversity of blood–brain barrier alteration and macrophage invasion in experimental autoimmune encephalomyelitis: A comparative MRI study

Ladewig, G., Jestaedt, L., Misselwitz, B., Solymosi, L., Toyka, K. V., Bendszus, M., & Stoll, G. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.08.027 · Cited by 45

Ring-enhancement in multiple sclerosis: marker of disease severity

Morgen, K., Jeffries, N. O., Stone, R. D., Martinꝉ, R., Richert, N. D., Frank, J. A., & McFarland, H. F. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700306 · Cited by 45

Long-term dynamics of multiple sclerosis iron rim lesions

Weber, C. E., Wittayer, M., Kraemer, M., Dabringhaus, A., Bail, K., Platten, M., Schirmer, L., Gass, A., & Eisele, P. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103340 · Cited by 43

Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study

Lavorgna, L., Bonavita, S., Ippolito, D., Lanzillo, R., Salemi, G., Patti, F., Valentino, P., Coniglio, G., Buccafusca, M., Paolicelli, D., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513494958 · Cited by 44

Enhanced magnetic resonance imaging in multiple sclerosis

Filippi, M. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600505 · Cited by 43

Interferon β-1b–neutralizing antibodies 5 years after clinically isolated syndrome

Hartung, H., Freedman, M. S., Polman, C. H., Edan, G., Kappos, L., Miller, D. H., Montalbán, X., Barkhof, F., Petkau, J., White, R., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822c90d7 · Cited by 43

Improved detectability of experimental allergic encephalomyelitis in excised swine spinal cords by high b-value q-space DWI

Biton, I. E., Mayk, A., Kidron, D., Assaf, Y., & Cohen, Y. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.06.011 · Cited by 43

Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis.

Rovaris, M., Comi, G., Ladkani, D., Wolinsky, J. S., & Filippi, M. (2003) · PubMed Central · Cited by 43

MRI to Monitor Treatment Efficacy in Multiple Sclerosis

Fazekas, F., Sørensen, P. S., Comı, G., & Filippi, M. (2007) · Journal of Neuroimaging · doi:10.1111/j.1552-6569.2007.00138.x · Cited by 42

Time-Series Modeling of Multiple Sclerosis Disease Activity: A Promising Window on Disease Progression and Repair Potential?

Meier, D., Weiner, H. L., & Guttmann, C. R. G. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2007.05.008 · Cited by 39

Segmentation of gadolinium‐enhanced lesions on MRI in multiple sclerosis

Datta, S., Sajja, B. R., He, R., Gupta, R. K., Wolinsky, J. S., & Narayana, P. A. (2007) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.20896 · Cited by 41

A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives

D’Amico, E., Patti, F., Zanghì, A., & Zappia, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101725 · Cited by 41

CSF β-amyloid as a putative biomarker of disease progression in multiple sclerosis

Pietroboni, A., di Cola, F. S., Scarioni, M., Fenoglio, C., Spanó, B., Arighi, A., Cioffi, S. M. G., Oldoni, E., Riz, M. D. D., Basilico, P., et al. (2017) · Multiple Sclerosis · doi:10.1177/1352458516674566 · Cited by 38

Automatic segmentation of gadolinium-enhancing lesions in multiple sclerosis using deep learning from clinical MRI

Gaj, S., Ontaneda, D., & Nakamura, K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255939 · Cited by 42

The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis

Branger, P., Parienti, J., Sormani, M. P., & Defer, G. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149685 · Cited by 40

T1 HYPOINTENSITIES AND AXONAL LOSS

Barkhof, F., Karas, G. B., & van Walderveen, M. A. A. (2000) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(25)00671-9 · Cited by 40

The use of transcranial magnetic stimulation in diagnosis, prognostication and treatment evaluation in multiple sclerosis

Simpson, M. A., & Macdonell, R. A. L. (2015) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2015.06.014 · Cited by 39

Power estimation for non-standardized multisite studies

Keshavan, A., Paul, F., Beyer, M. K., Zhu, A. H., Papinutto, N., Shinohara, R. T., Stern, W. A., Amann, M., Bakshi, R., Bischof, A., et al. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.03.051 · Cited by 38

Ultrashort echo time (UTE) magnetic resonance imaging of myelin: technical developments and challenges

Ma, Y., Jang, H., Chang, E. Y., Hiniker, A. O., Head, B. P., Lee, R. R., Corey‐Bloom, J., Bydder, G. M., & Du, J. (2020) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-20-541 · Cited by 37

A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis

Baumhackl, U., Franta, C., Retzl, J., Salomonowitz, E. K., & Eder, G. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00815-0 · Cited by 37

Lesion enhancement diminishes with time in primary progressive multiple sclerosis

Khaleeli, Z., Ciccarelli, O., Mizskiel, K., Altmann, D. R., Miller, D., & Thompson, A. J. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458509358090 · Cited by 37

A composite score to predict short-term disease activity in patients with relapsing-remitting MS

Sormani, M. P., Rovaris, M., Comi, G., & Filippi, M. (2007) · Neurology · doi:10.1212/01.wnl.0000276940.90309.15 · Cited by 37

Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course

Cook, S. D., Dhib-Jalbut, S. S., Dowling, P. C., Durelli, L., Ford, C. C., Giovannoni, G., Halper, J., Harris, C. J., Herbert, J., Li, D., et al. (2012) · International Journal of MS Care · doi:10.7224/1537-2073-14.3.105 · Cited by 39

Estimating individual treatment effect on disability progression in multiple sclerosis using deep learning

Falet, J.-P. R., Durso-Finley, J., Nichyporuk, B., Schroeter, J., Bovis, F., Sormani, M. P., Precup, D., Arbel, T., & Arnold, D. L. (2022) · Nature Communications · doi:10.1038/s41467-022-33269-x · Cited by 36

Disability in multiple sclerosis: When synaptic long-term potentiation fails

Weiss, S., Mori, F., Rossi, S., & Centonze, D. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.03.023 · Cited by 36

Composite MRI scores improve correlation with EDSS in multiple sclerosis

Poonawalla, A. H., Datta, S., Juneja, V., Nelson, F. M., Wolinsky, J. S., Cutter, G., & Narayana, P. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510374892 · Cited by 36

An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis

Vartanian, T. K. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90013-0 · Cited by 36

Longitudinal MRI study

Markovic‐Plese, S., Bielekova, B., Kadom, N., Leist, T. P., Martinꝉ, R., Frank, J. A., & McFarland, H. F. (2003) · Neurology · doi:10.1212/01.wnl.0000071218.34009.af · Cited by 36

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

Goodin, D. S., Hartung, H.-P., O'Connor, P. W., Filippi, M., Arnason, B. G. W., Comi, G., Cook, S. D., Jeffery, D., Kappos, L., Bogumil, T., et al. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511418629 · Cited by 35

Leveraging electronic health records data to predict multiple sclerosis disease activity

Ahuja, Y., Kim, N. H., Liang, L., Cai, T. A., Dahal, K. P., Seyok, T., Chen, L., Finan, S., Liao, K. P., Savovoa, G., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51324 · Cited by 33

Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes

Katrych, O., Simone, T. M., Azad, S., & Mousa, S. A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824598 · Cited by 35

Synthetic Post-Contrast Imaging through Artificial Intelligence: Clinical Applications of Virtual and Augmented Contrast Media

Pasquini, L., Napolitano, A., Pignatelli, M., Tagliente, E., Parrillo, C., Nasta, F., Romano, A., Bozzao, A., & Napoli, A. D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112378 · Cited by 38

The added value of spinal cord lesions to disability accrual in multiple sclerosis

Ruggieri, S., Prosperini, L., Petracca, M., Logoteta, A., Tinelli, E., Giglio, L. D., Ciccarelli, O., Gasperini, C., & Pozzilli, C. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11829-5 · Cited by 41

Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis.

Koudriavtseva, T., Thompson, A. J., Fiorelli, M., Gasperini, C., Bastianello, S., Bozzao, A., Paolillo, A., Pisani, A., Galgani, S., & Pozzilli, C. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.3.285 · Cited by 95

The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results

Losseff, N. A., Miller, D. H., Kidd, D. P., & Thompson, A. J. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700105 · Cited by 31

Clinical and Magnetic Resonance Imaging Predictors of Disability in Primary and Secondary Progressive Multiple Sclerosis

Losseff, N. A., Kingsley, D. P. E., McDonald, W. I., Miller, D., & Thompson, A. J. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600100406 · Cited by 73

Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis

Tortorella, C., Bellacosa, A., Paolicelli, D., Fuiani, A., Monte, E. D., Simone, I. L., Giaquinto, P., Livrea, P., & Trojano, M. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.08.006 · Cited by 70

Resonancia magnética con gadolinio en la fase aguda de las recaídas en esclerosis múltiple

Salas, P. A. O., Silva, J. B., Lopez, L. C., Vergara, K. R., & Rovira, À. (2017) · Revista de Neurología · doi:10.33588/rn.6406.2016310 · Cited by 4